CONJUGATE COMPOSITION COMPRISING ANTIBODIES AGAINST CD40 OR CD28

Details for Australian Patent Application No. 2003285483 (hide)

Owner ADJUVANTIX LIMITED

Inventors HEATH, Andrew

Pub. Number AU-A-2003285483

PCT Number PCT/GB2003/0047

PCT Pub. Number WO2004/041866

Priority 0225736.8 05.11.02 GB

Filing date 3 November 2003

Wipo publication date 7 June 2004

International Classifications

C07K 016/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 039/44 Medicinal preparations containing antigens or antibodies - Antibodies bound to carriers

C12N 005/16 Undifferentiated human, animal or plant cells, e.g. cell lines - Animal cells

C07K 019/00 Hybrid peptides

C07K 014/195 Peptides having more than 20 amino acids - from bacteria

A61K 039/39 Medicinal preparations containing antigens or antibodies - characterised by the immunostimulating additives, e.g. chemical adjuvants

A61K 039/385 Medicinal preparations containing antigens or antibodies - Haptens or antigens, bound to carriers

Event Publications

1 April 2004 Complete Application Filed

  Priority application(s): 0225736.8 05.11.02 GB

1 July 2004 Application Open to Public Inspection

  Published as AU-A-2003285483

21 July 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003285484-POLYMER

2003285482-METHODS AND MEANS FOR THE TREATMENT OF INFLAMMATORY DISORDERS